* Spruce Biosciences Inc reported a quarterly adjusted loss of 28 cents per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of -40 cents. The mean expectation of seven analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -34 cents to -19 cents per share.
* Revenue rose 1.9% to $2.00 million from a year ago; analysts expected $1.16 million.
* Spruce Biosciences Inc's reported EPS for the quarter was a loss of 28 cents.
* The company reported a quarterly loss of $11.63 million.
* Spruce Biosciences Inc shares had risen by 6.0% this quarter and lost 71.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 22.3% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"
Wall Street's median 12-month price target for Spruce Biosciences Inc is $2.50 This summary was machine generated from LSEG data May 13 at 08:46 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.29 -0.28 Beat
Dec. 31 2023 -0.39 -0.24 Beat
Sep. 30 2023 -0.35 -0.30 Beat
Jun. 30 2023 -0.39 -0.32 Beat
Comments